Oric director-linked entity sells 300 ORIC shares

Oric Pharmaceuticals director Richard A. Heyman, through an associated entity, reported a small insider sale of Oric Pharmaceuticals, Inc. common stock.

Rhea-AI Filing Summary

Oric Pharmaceuticals director Richard A. Heyman, through an associated entity, reported a small insider sale of Oric Pharmaceuticals, Inc. common stock.

RAHD Capital, LLC, an entity for which Heyman has voting and investment power, sold 300 shares of common stock at $12.00 per share in an open-market transaction on July 6, 2026, executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, RAHD Capital, LLC held 212,772 shares indirectly, while Heyman also reported a separate direct holding entry showing 41,800 shares owned directly.

Insider Trade Summary 10b5-1

Net Seller: 300 shares

Net Sell 2 txns

Insider Heyman Richard A.

Role Director

Sold 300 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	300	$12.00	$4K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 212,772 shares (Indirect, See footnote); Common Stock — 41,800 shares (Direct)

Footnotes (2)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
2. F2. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

Key Figures

Shares sold: 300 shares Sale price: $12.00 per share Indirect holdings after sale: 212,772 shares +1 more

4 metrics

Shares sold 300 shares Open-market sale on July 6, 2026

Sale price $12.00 per share Common stock transaction code S

Indirect holdings after sale 212,772 shares Held by RAHD Capital, LLC following transaction

Direct holdings 41,800 shares Common stock directly owned after holding entry

Key Terms

Rule 10b5-1 trading plan, open-market sale, indirect ownership, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale for 300.0000 shares of Common Stock at 12.0000 per share."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"direct_or_indirect: I, nature_of_ownership: See footnote, indicating indirect ownership through RAHD Capital, LLC."

Common Stock financial

"security_title: Common Stock for both the holding entry and the sale transaction."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ORIC director Richard A. Heyman report?

Richard A. Heyman reported an indirect open-market sale of 300 Oric Pharmaceuticals common shares at $12.00 each. The sale was executed by RAHD Capital, LLC, an entity he controls, under a pre-arranged Rule 10b5-1 trading plan dated July 6, 2026.

How many ORIC shares did RAHD Capital, LLC hold after the reported sale?

After selling 300 shares, RAHD Capital, LLC held 212,772 Oric Pharmaceuticals common shares indirectly. Richard A. Heyman has voting and investment power over these shares, according to the filing’s footnote, reflecting his ongoing substantial indirect ownership position in the company.

Was the ORIC insider sale made under a Rule 10b5-1 trading plan?

Yes, the 300-share sale of Oric Pharmaceuticals stock was executed under a Rule 10b5-1 trading plan. The plan was adopted by Richard A. Heyman and RAHD Capital, LLC, indicating the transaction was pre-arranged rather than an opportunistic, discretionary market trade.

What is the reported sale price for the ORIC insider transaction?

The reported sale price for the Oric Pharmaceuticals insider transaction was $12.00 per share. RAHD Capital, LLC sold 300 common shares at this price in an open-market or private transaction, as described in the Form 4 transaction details and code explanation.

What are Richard A. Heyman’s direct ORIC share holdings after the filing?

Following the reported transactions, Richard A. Heyman directly held 41,800 Oric Pharmaceuticals common shares. This direct holding is separate from the 212,772 shares held indirectly through RAHD Capital, LLC, giving him both direct and indirect exposure to the company’s equity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 04:35 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heyman Richard A.

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		S(1)		300	D	$12	212,772	I	See footnote(2)
Common Stock								41,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.

2. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

	/s/ Christian Kuhlen, attorney-in-fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)